Craft

BiondVax

Stock Price

$3.6

2024-10-29

Market Capitalization

$3.1 M

2024-10-29

Revenue

$1.3 M

FY, 2025

BiondVax Summary

Company Summary

Overview
BiondVax Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate. It is designed to provide multi-season and multi-strain protection against human influenza virus strains, both seasonal and pandemic.
Type
Public
Status
Active
Founded
2003
HQ
Jerusalem, IL | view all locations
Website
http://www.biondvax.com/
Cybersecurity rating
Sectors

Key People

  • Mark Germain

    Mark Germain, Chairman of the Board

    • Ron Babecoff

      Ron Babecoff, Founder, President and CEO, Director

      • Tamar Ben-Yedidia

        Tamar Ben-Yedidia, Chief Scientific Officer

        • Shai Ashkenazi

          Shai Ashkenazi, Medical Director

          LocationsView all

          1 location detected

          • Jerusalem, Jerusalem District HQ

            Israel

          BiondVax Financials

          Summary Financials

          Revenue (FY, 2025)
          $1.3M
          Gross profit (FY, 2025)
          ($2.7M)
          Net income (FY, 2025)
          ($8.3M)
          Cash (FY, 2025)
          $1.7M
          EBIT (FY, 2025)
          ($7.5M)
          Enterprise value
          $1.7M

          Footer menu